Lista de obras - Silvia Ratto-Kim - Dominio Público Uruguay

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

article

Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.

artículo científico publicado en 2014

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

artículo científico publicado en 2016

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

artículo científico publicado en 2002

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

artículo científico publicado en 2014

Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection

artículo científico publicado en 2012

Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

article

Comparison of HIV-1 envelope-specific CD4+ T cell lines simultaneously established from peripheral blood mononuclear cells and lymph node biopsy in HIV-1-infected individuals ⬇️

artículo científico publicado el 15 de noviembre de 1997

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

artículo científico publicado en 1997

Designing the epitope flanking regions for optimal generation of CTL epitopes.

artículo científico publicado en 2014

Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia

article

Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection.

artículo científico publicado en 2012

Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.

artículo científico publicado en 2012

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

artículo científico publicado en 2000

Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

artículo científico publicado en 2016

Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand

artículo científico publicado en 2008

Generation and Expansion of HIV-1 CD4+ Antigen-Specific T Cell Lines

article

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

artículo científico publicado en 2016

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses

artículo científico publicado en 2012

HIV-Associated Wasting in the Era of Highly Active Antiretroviral Therapy: A Syndrome of Residual HIV Infection in Monocytes and Macrophages?

article

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E ⬇️

artículo científico publicado el 12 de noviembre de 2011

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

artículo científico publicado en 2012

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

artículo científico publicado en 2015

Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons

artículo científico publicado en 2004

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

artículo científico publicado en 2012

Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans

artículo científico publicado en 2007

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120

artículo científico publicado en 2001

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

article

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial.

artículo científico publicado en 2009

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial

article

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial.

artículo científico publicado en 2009

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment

artículo científico publicado en 2007

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

artículo científico publicado en 2010

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals

artículo científico publicado en 2014

Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.

artículo científico publicado en 2004

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

artículo científico publicado en 2017

S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.

artículo científico publicado en 2009

Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost

artículo científico publicado en 2017

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

artículo científico publicado en 2016

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene.

artículo científico publicado en 2012

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

artículo científico publicado en 2004

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

artículo científico publicado en 2003

Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection

article

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

artículo científico publicado en 2016

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection

artículo científico publicado en 2012

TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1

artículo científico publicado en 2015

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

artículo científico publicado el 23 de abril de 2012

Varicella immunity: persistent serologic non-response to immunization

article

Lista de obras de Silvia Ratto-Kim

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection

Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

Comparison of HIV-1 envelope-specific CD4+ T cell lines simultaneously established from peripheral blood mononuclear cells and lymph node biopsy in HIV-1-infected individuals ⬇️

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

Designing the epitope flanking regions for optimal generation of CTL epitopes.

Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia

Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection.

Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand

Generation and Expansion of HIV-1 CD4+ Antigen-Specific T Cell Lines

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses

HIV-Associated Wasting in the Era of Highly Active Antiretroviral Therapy: A Syndrome of Residual HIV Infection in Monocytes and Macrophages?

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E ⬇️

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial.

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial.

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals

Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.

Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene.

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection

TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

Varicella immunity: persistent serologic non-response to immunization